Synapse
⌘+K
Synapse
PulseExploreJournal ClubResearchersJournals
Instagram
HomeJournal ClubExplore
May 6, 2026Circulation

Abstract TH958: Cardiovascular Risk Stratification Among United States Adults with Metabolic Dysfunction–Associated Steatotic Liver Disease

View Full Paper
Ask AI
Bookmark
Share

Authors

JCJingyao ChenSSShanshan SongMOMichelle Ogunwole

Discussion

Loading...

Member takes

Overview

Analysis reveals cardiovascular disease risk increases with metabolic risk factors in adults with MASLD, suggesting targeted prevention strategies may reduce risks.

Key Points

  • This research aims to evaluate how cardiovascular risk varies based on metabolic risk factors in US adults with MASLD.
  • Analyzed data from the National Health and Nutrition Examination Survey (2017-March 2020) to identify adults with MASLD.
  • Defined MASLD with hepatic steatosis and at least one metabolic risk factor like obesity or type II diabetes.
  • Classified participants by number of metabolic risk factors (1-2, 3, 4+) and calculated 10-year cardiovascular risks using PREVENT Equations.
  • Used survey-weighted linear regression to assess associations between MASLD category and cardiovascular outcomes.
  • 186 participants were included, representing approximately 4.2 million US adults with MASLD.
  • Higher predicted risks for total CVD (+8%), ASCVD (+5%), and heart failure (+6%) were found in those with ≥4 risk factors.
  • Statistically significant increases in PREVENT scores were noted with more metabolic risk factors (p<0.05).

Cite This Study

Chen et al. (2026) studied this question.

synapsesocial.com/papers/69fa979b04f884e66b531872https://doi.org/10.1161/cir.153.suppl_1.th958
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Metabolic dysfunction-associated steatotic liver disease increases cardiovascular disease risk in young adults2025 · 30 citations
  2. 2impact of different cardiometabolic risk factors in MASLD: rethinking overweight/obesity criteria2024 · 5 citations
  3. 3Risk stratification for patients with MASLD based on cardiometabolic risk factors2026
  4. 4Abstract MPTH69: Metabolic Dysfunction-Associated Steatotic Liver Disease Across the Cardiovascular-Kidney-Metabolic Spectrum: Insights from the CARDIA Study2026
  5. 5Prevalence, proportions of elevated liver enzyme levels, and long‐term cardiometabolic mortality of patients with metabolic dysfunction‐associated steatotic liver disease2024 · 8 citations